



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/572,543
				Filing Date	March 17, 2006
				First Named Inventor	Darcey Clark
				Art Unit	0
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	27866/39370A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-20030069284-A1	04-10-2003	Keegan et al.	
	A2	US-20030162785-A1	08-28-2003	Lin et al.	
	A3	US-20030199511-A1	10-23-2003	Li et al.	
	A4	US-20040014765-A1	01-22-2004	Boyle et al.	
	A5	US-20040092535-A1	05-13-2004	Barsanti et al.	
	A6	US-6,211,164	04-03-2001	Luo et al.	
	A7	US-6,495,586-A1	12-17-2002	Jacobs et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-98/53050				
	B2	WO-99/17769				
	B3	WO-00/16781				
	B4	WO-01/53268				
	B5	WO-01/53274				
	B6	WO-01/57206				
	B7	WO-US02/06452				
	B8	WO-02/070494				
	B9	WO-02/070515				
	B10	WO-02/16326				
	B11	WO-03/004488				
	B12	WO-03/028724				
	B13	WO-03/028731				
	B14	WO-03/029241				
	B15	WO-03/029242				
	B16	WO-03/037886				
	B17	WO-03/051838				
	B18	WO-03/101444				
	B19	WO-04/018419				
	B20	WO-2002/070494				
	B21	WO-2003/091255				
	B22	WO-2004/014876				
	B23	WO-2004/048343				
	B24	WO-2004/063198				
	B25	WO-2006/014359				
	B26	WO-2006/021002				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Examiner Signature	/Christopher Stone/	Date Considered	02/05/2008
-----------------------	---------------------	--------------------	------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/572,543
				Filing Date	March 17, 2006
				First Named Inventor	Darcey Clark
				Art Unit	0
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	27866/39370A

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Ajiro et al., <i>J. Biol. Chem.</i> , Vol. 271, pp.13197-13201 (1996).		
	C2	Andreaseen et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 86, pp.2272-2276 (1992).		
	C3	Baker et al., <i>Genes Dev.</i> , Vol. 8, pp.2416-2488 (1994).		
	C4	Blasina et al., <i>Curr. Biol.</i> , Vol. 9, pp.1-10 (1999).		
	C5	Bracey et al., <i>Clin. Cancer Res.</i> , Vol. 3, pp.1371-1381 (1997).		
	C6	Bradley et al., <i>Clin. Cancer Res.</i> , Vol. 7, pp.3229 (2001).		
	C7	Bunz et al., <i>Science</i> , Vol. 282, pp.1497-1501 (1998).		
	C8	Carr, <i>Science</i> , Vol. 271, pp.314-315 (1996).		
	C9	Cerra et al., <i>Methods in Cell Biology</i> , Vol. 33, pp.1-12 (1990).		
	C10	Chen et al., <i>Oncogene</i> , Vol. 18, pp.249-256 (1999).		
	C11	Connell-Crowley et al., <i>Mol. Biol. Cell</i> , Vol. 8, pp.287-301 (1997).		
	C12	Fan et al., <i>Cancer Res.</i> , Vol. 55, pp.1649-1654 (1995).		
	C13	Feijoo et al., <i>J. Cel Biol.</i> , Vol. 154, pp.913-923 (2001).		
	C14	Furnari et al., <i>Science</i> , Vol. 277, pp.1495-1497 (1997).		
	C15	Gandhi et al., <i>J. Clin. Ocol.</i> , Vol. 20, pp.665-673 (2002).		
	C16	Gatei et al., <i>J. Biol. Chem.</i> , Vol. 278, pp.14806-14811 (2003).		
	C17	Gesner, Abstract at SRI Conference: Protein Phosphorylation and Drug Discovery World Summit, (2003).		
	C18	Gijbels et al., <i>Exp. Dermatol.</i> , Vol. 9, pp.351-358 (2000).		
	C19	Goto et al., <i>J. Biol. Chem.</i> , Vol. 274, pp.25543-25549 (1999).		
	C20	Grant et al., <i>Drug Resistance Updates</i> , Vol. 6, pp.15-26 (2003).		
	C21	Guo et al., <i>Genes Dev.</i> , Vol. 14, pp.2745-2756 (2000).		
	C22	Hartwell et al., <i>Science</i> , Vol. 246, pp.629-634 (1989).		
	C23	Hartwell et al., <i>Science</i> , Vol. 266, pp.1821-1828 (1994).		
	C24	Hirose et al., <i>Cancer Res.</i> , Vol. 61, pp.5843-5849 (2001).		
	C25	Levine, <i>Cell</i> , Vol. 88, pp.3234-3331 (1997).		
	C26	Liu et al., <i>Genes Dev.</i> , Vol. 14, pp.1448-1459 (2000).		
	C27	Lopez-Girona et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 98, pp.11289-11294 (2001).		
	C28	Mack et al., <i>Cancer Chemother Pharmacol.</i> , Vol. 51, No. 4, pp.337-348 (2003).		
	C29	Matsuoka et al., <i>Science</i> , Vol. 282, pp.1893-1897 (1998).		
	C30	Ng et al., <i>J. Biol. Chem.</i> , Vol. 279, No. 10, pp.8808-8819 (2004).		
	C31	O'Connell et al., <i>EMBO J.</i> , Vol. 16, pp.545-554 (1997).		
	C32	Sanchez et al., <i>Science</i> , Vol. 277, pp.1497-1501 (1997).		
	C33	Sanchez et al., <i>Science</i> , Vol. 286, pp.1166-1171 (1999).		
	C34	Schultz et al., <i>J. Med. Chem.</i> , Vol. 42, No. 15, pp.2909-2919 (1999).		

Baker et :

Examiner Signature	/Christopher Stone/	Date Considered	02/05/2008
--------------------	---------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/572,543
				Filing Date	March 17, 2006
				First Named Inventor	Darcey Clark
				Art Unit	0
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	27866/39370A

	C35	Sedlacek et al., <i>Int. J. Oncol.</i> , Vol. 9, pp.1143-1168 (1996).	
	C36	Shi et al., <i>Cancer Res.</i> , Vol. 61, pp.1065-1072 (2001).	
	C37	Sorensen et al., <i>Cancer Cell</i> , Vol. 3, No. 3, pp.247-258 (2003).	
	C38	Stojic et al., <i>Genes Dev.</i> , Vol. 18, No. 11, pp.1331-1344 (2004).	
	C39	Tenzer et al., <i>Curr. Med. Chem. Anti-Cancer Agents</i> , Vol. 3, pp.35-46 (2003).	
	C40	Wang et al., <i>Natl. Acad. Sci. (USA)</i> , Vol. 100, No. 26, pp.15387-15392 (2003).	
	C41	Weinberg, <i>Cell</i> , Vol. 81, pp.323-330 (1995).	
	C42	Weinert et al., <i>Genes and Development</i> , Vol. 8, pp.652 (1994).	
	C43	Xiao et al., <i>J. Biol. Chem.</i> , Vol. 278, No. 24, pp.21767-21773 (2003).	
	C44	Yin et al., <i>Biochem. Biophys. Res. Commun.</i> , Vol. 295, pp.435-444 (2002).	
	C45	Zhao et al., <i>Mol. Cell Biol.</i> , Vol. 21, pp.4129-4139 (2001).	
	C46	Zhao et al., <i>PNAS USA</i> , Vol. 99, pp.14795-14800 (2002).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Christopher Stone/	Date Considered	02/05/2008
--------------------	---------------------	-----------------	------------

941915

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./